undamentalytics Newsletter
Sign in

Inmed Pharmaceuticals Inc. (INM) stock

Add to watchlist

Add holding +

NASDAQ: INM Nasdaq Biotechnology Next results ~November 5, 2026

Inmed Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Inmed Pharmaceuticals Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling49 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds13 adding, 5 cuttingOf 4 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Inmed Pharmaceuticals Inc.'s trailing-twelve-month revenue fell 6.7% year on year, with a free-cash-flow margin of -172.1%.

Current signal Net margin expanding: TTM net margin reached -26.7%, up 137.1pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 1209.3 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 6.7% over the last 12 months.
  • Loss-making. Operating margin is -147.9%: costs exceed revenue.
  • Burning cash. Free cash flow was -172.1% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 154% and a beta of 0.2 against the S&P 500.
  • Growth easing. The growth rate is 3.5 points lower than a quarter earlier.
  • Gross margin slipping. Gross margin is down 5.7 points on a year ago.

Latest results: FY2026 Q2

Filed February 11, 2026
Revenue
$1m, down 26.2% on a year earlier
Next report
November 5, 2026

Inmed Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.9%
  • 1 week+2.5%
  • 1 month+22.6%
  • This year+53.8%
  • 1 year-13.3%
  • 5 years-99.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.5M
Net margin
-26.7%
EPS (TTM, diluted)
$-2.90

Growth

Revenue growth
−6.7%
Change in growth rate
−3.5 pts

Cash

Free cash flow (TTM)
-$7.9M
FCF margin
-172.1%
Stock pay % of revenue
2.5%

Earnings

Last results
November 13, 2020

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Inmed Pharmaceuticals Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025
Share price$1590.00$235.00$18.54$5.32$3.25
Market value$128m$20m$7m$2m$3m
+ Net debt (− = net cash)−$7m−$6m−$9m−$7m−$11m
Enterprise value$121m$14m−$2m−$5m−$8m
Multiples
Price / sales 67.3x18.1x1.6x0.4x0.6x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close.

Analysts' consensus

No analyst estimates are published for Inmed Pharmaceuticals Inc.: too few analysts cover it.

Positioning

Short interest
0.1%
of tradable shares
Days to cover
0.11
at average volume
Short interest, 1 month
−58%
to October 15, 2026
Held by institutions
53%
of shares
Held by insiders
0.1%
of shares
Employees
6
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
INM−60%−94%−79%−43%−78%+54%
Industry peers (median)−35%−56%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
INM42%17%25%42%17%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
INM−76%−96%−86%−72%−79%−52%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from January 3, 2018 to March 30, 2026. Getting back needed a 5070632% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.61 – $1.85
From 52-week high
−11.9%
vs 50-day average
+17.8%
vs 200-day average
+35.3%
Volatility (1 year)
154%
Beta vs S&P 500
0.23

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±4.6%
After a week
0 up, 1 down
typical move ±1.2%
After a month
0 up, 1 down
typical move ±8.0%
Results releasedNext dayS&P 500 next day5 days21 days
November 13, 2020 +4.6% +2.6% −1.2% −8.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Inmed Pharmaceuticals Inc.
$2M $3M $4M $5M $6M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $2.3M Revenue (TTM), FY23 Q4: $4.1M Revenue (TTM), FY24 Q1: $4.7M Revenue (TTM), FY24 Q2: $5.5M Revenue (TTM), FY24 Q3: $5.6M Revenue (TTM), FY24 Q4: $4.6M Revenue (TTM), FY25 Q1: $5M Revenue (TTM), FY25 Q2: $4.8M Revenue (TTM), FY25 Q3: $4.9M Revenue (TTM), FY25 Q4: $4.9M Revenue (TTM), FY26 Q1: $4.8M Revenue (TTM), FY26 Q2: $4.5M $4.5M

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $2.3M
FY23 Q4 $4.1M
FY24 Q1 $4.7M
FY24 Q2 $5.5M
FY24 Q3 $5.6M
FY24 Q4 $4.6M
FY25 Q1 $5M
FY25 Q2 $4.8M
FY25 Q3 $4.9M
FY25 Q4 $4.9M
FY26 Q1 $4.8M
FY26 Q2 $4.5M
Revenue growth, TTM YoY Inmed Pharmaceuticals Inc.
-100% 0% 100% 200% 300% FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue growth, TTM YoY, FY24 Q1: 234.5% Revenue growth, TTM YoY, FY24 Q2: 239.8% Revenue growth, TTM YoY, FY24 Q3: 140.5% Revenue growth, TTM YoY, FY24 Q4: 11.2% Revenue growth, TTM YoY, FY25 Q1: 5.2% Revenue growth, TTM YoY, FY25 Q2: -11.9% Revenue growth, TTM YoY, FY25 Q3: -12.5% Revenue growth, TTM YoY, FY25 Q4: 7.5% Revenue growth, TTM YoY, FY26 Q1: -3.3% Revenue growth, TTM YoY, FY26 Q2: -6.7% -6.7%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 234.5%
FY24 Q2 239.8%
FY24 Q3 140.5%
FY24 Q4 11.2%
FY25 Q1 5.2%
FY25 Q2 -11.9%
FY25 Q3 -12.5%
FY25 Q4 7.5%
FY26 Q1 -3.3%
FY26 Q2 -6.7%
Operating margin (TTM) Inmed Pharmaceuticals Inc.
-1500% -1000% -500% 0% FY23 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY24 Q1 Operating margin (TTM), FY23 Q1: -1357.1% Operating margin (TTM), FY23 Q2: -1050.0% Operating margin (TTM), FY23 Q3: -661.7% Operating margin (TTM), FY23 Q4: -192.2% Operating margin (TTM), FY24 Q1: -147.9% -147.9%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q1 -1357.1%
FY23 Q2 -1050.0%
FY23 Q3 -661.7%
FY23 Q4 -192.2%
FY24 Q1 -147.9%
FCF margin (TTM) Inmed Pharmaceuticals Inc.
-600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -456.2% FCF margin (TTM), FY23 Q4: -176.1% FCF margin (TTM), FY24 Q1: -152.7% FCF margin (TTM), FY24 Q2: -115.5% FCF margin (TTM), FY24 Q3: -117.6% FCF margin (TTM), FY24 Q4: -151.9% FCF margin (TTM), FY25 Q1: -133.8% FCF margin (TTM), FY25 Q2: -150.9% FCF margin (TTM), FY25 Q3: -142.6% FCF margin (TTM), FY25 Q4: -163.9% FCF margin (TTM), FY26 Q1: -171.0% FCF margin (TTM), FY26 Q2: -172.1% -172.1%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -456.2%
FY23 Q4 -176.1%
FY24 Q1 -152.7%
FY24 Q2 -115.5%
FY24 Q3 -117.6%
FY24 Q4 -151.9%
FY25 Q1 -133.8%
FY25 Q2 -150.9%
FY25 Q3 -142.6%
FY25 Q4 -163.9%
FY26 Q1 -171.0%
FY26 Q2 -172.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025 LTM Dec 2025
Income
Revenue 2 1 4 5 5 5
Gross profit — 1 1 1 2 1
EBITDA −10 −18 −8 — — —
Operating income −10 −19 −8 — — —
Net income −10 −19 −8 −8 −2 −1
Diluted EPS −$126.53 −$221.13 −$21.67 −$20.14 −$8.36 —
Growth (year on year)
Revenue — −42.8% +279.6% +11.2% +7.5% −6.7%
Margins
Gross margin — 49.9% 33.9% 23.9% 34.5% 29.7%
EBITDA margin −529.5% <−999% −187.3% — — —
Operating margin −535.9% <−999% −192.2% — — —
Net margin −535.9% <−999% −192.2% −166.9% −34.4% −26.7%
Free-cash-flow margin −514.3% <−999% −180.0% −152.1% −163.9% −172.1%
Cash flow
Cash from operations −10 −16 −7 −7 −8 −8
Capital spending 0 0 0 0 0 0
Free cash flow −10 −16 −7 −7 −8 −8
Stock-based pay 1 1 0 0 0 0
Free cash flow after stock pay −10 −16 −8 −7 −8 −8
Balance sheet
Cash 7 6 9 7 11 7
Total debt 0 0 0 0 0 0
Net debt (negative = net cash) −7 −6 −9 −7 −11 −7
Diluted shares — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 0 checks passed · September 30, 2026
  • Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Inmed Pharmaceuticals Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
49.0%
of revenue
Days sales outstanding
15 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated INM ENSC OCGN TRDA BOLT CRIS Median
Revenue, last 12 months $5m $5m $5m $5m $5m $4m $55m
Revenue growth, last 12 months −6.7% −39.3% −3.7% −94.1% 12.8% −62.2% 12.2%
Revenue growth, 3-year average 40.8% 14.6% 26.3% — −11.5% −25.0% 14.3%
Revenue growth, latest quarter −26.2% −15.1% 8.4% −53.9% −99.7% −100.0% 10.2%
Operating margin −147.9% −281.3% <−999% <−999% −654.5% −203.2% −187.2%
Operating margin, 3-year average — −347.6% <−999% <−999% −887.4% −341.2% −363.5%
Net margin −26.7% −280.5% <−999% <−999% −611.5% −490.3% −163.5%
Cash from operations / revenue −172.1% −196.8% <−999% <−999% −669.2% −709.0% −168.8%
Free-cash-flow margin −172.1% −197.2% <−999% <−999% −669.2% −709.0% −168.1%
Free-cash-flow margin, 3-year average −146.2% −165.8% <−999% <−999% −825.2% −465.5% −306.5%
Stock pay / revenue 2.5% 1.8% 201.1% 413.3% 54.1% 66.4% 19.2%
Change in share count — 74.6% 14.1% −0.6% 1.0% 90.7% 8.2%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$4.2M
Institutions reporting
19
Shares held vs prior quarter
▲ 744.9%
Positions opened / closed
13 / 2

Top buyers and sellers, Q2 2026: 13 institutions bought and 5 sold ; the biggest buyer was ADAR1 Capital Management, LLC (+800K shares) and the biggest seller Sabby Management, LLC (−175K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
ADAR1 Capital Management, LLC $1.2M 800K 29.7% New
Vivo Capital, LLC $1.2M 798K 29.6% New
Squadron Capital Management LLC $503,750 325K 12.0% New
Ikarian Capital, LLC $379,788 245K 9.1% New
Ursa Fund Management, LLC $194,990 126K 4.7% New
Montanova Capital, LLC $155,000 100K 3.7% New
Boothbay Fund Management, LLC $115,078 74K 2.8% New
Sabby Management, LLC $69,704 45K 1.7% ▼ 79.6%
Jane Street Group, LLC $66,771 43K 1.6% New
Venrock Adviser, LLC $50,662 33K 1.2% New
Citadel Advisors LLC $40,430 26K 1.0% ▼ 44.5%
Seven Grand Managers, LLC $38,750 25K 0.9% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Inmed Pharmaceuticals Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $1.4M 49 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $1.4M net buying
Insider Date Trade Shares Price Value
Adar1 Capital Management, Llc 10% owner October 23, 2026 Buy 4 $1.32 $5
Adar1 Capital Management, Llc 10% owner October 19, 2026 Buy 1,086 $1.32 $1,434
Adar1 Capital Management, Llc 10% owner October 16, 2026 Buy 1 $1.32 $1
Adar1 Capital Management, Llc 10% owner October 15, 2026 Buy 984 $1.32 $1,301
Adar1 Capital Management, Llc 10% owner October 14, 2026 Buy 8,021 $1.33 $10,668
Adar1 Capital Management, Llc 10% owner October 13, 2026 Buy 564 $1.33 $750
Adar1 Capital Management, Llc 10% owner October 8, 2026 Buy 2,256 $1.33 $2,997
Adar1 Capital Management, Llc 10% owner October 7, 2026 Buy 3,046 $1.33 $4,051
Adar1 Capital Management, Llc 10% owner October 6, 2026 Buy 5,601 $1.33 $7,436
Adar1 Capital Management, Llc 10% owner October 5, 2026 Buy 18,182 $1.33 $24,182
Adar1 Capital Management, Llc 10% owner October 2, 2026 Buy 8,307 $1.33 $11,048
Adar1 Capital Management, Llc 10% owner October 1, 2026 Buy 16,431 $1.33 $21,850

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • November 13, 2020

Recent SEC filings

Data status

When each part of this page on Inmed Pharmaceuticals Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Inmed Pharmaceuticals Inc. in brief

What does Inmed Pharmaceuticals Inc. do?
Inmed Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in June.
What is Inmed Pharmaceuticals Inc.'s stock ticker?
Inmed Pharmaceuticals Inc. trades under the ticker INM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Inmed Pharmaceuticals Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Inmed Pharmaceuticals Inc. reported revenue of $4.5M, 6.7% lower than a year earlier, according to its SEC filings.
What is Inmed Pharmaceuticals Inc.'s free cash flow?
Inmed Pharmaceuticals Inc.'s free-cash-flow margin is -172.1% of revenue over the trailing twelve months.
Who are Inmed Pharmaceuticals Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are ADAR1 Capital Management, LLC, Vivo Capital, LLC and Squadron Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Inmed Pharmaceuticals Inc.'s market cap?
On June 30, 2025, Inmed Pharmaceuticals Inc.'s market capitalisation was about $3.2M and net debt of -$10.7M. Market figures come from third-party market data and may be delayed.
Who are Inmed Pharmaceuticals Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Inmed Pharmaceuticals Inc. are Ensysce Biosciences, Inc., Ocugen, Inc., Entrada Therapeutics, Inc., Bolt Biotherapeutics, Inc. and Curis Inc. The side-by-side comparison below sets their revenue, margins and growth against Inmed Pharmaceuticals Inc.'s.
Are insiders buying or selling Inmed Pharmaceuticals Inc. stock?
Over the last 12 months, Inmed Pharmaceuticals Inc.'s directors and officers reported 49 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Inmed Pharmaceuticals Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Inmed Pharmaceuticals Inc. announces its own schedule.